12 results
8-K
EX-99.1
TLIS
Talis Biomedical Corp
27 Jul 23
Regulation FD Disclosure
8:30am
Biomedical. “The ability to lyse difficult targets and to purify and concentrate nucleic acids to deliver lab quality results in less than 30 minutes
8-K
EX-10.1
TLIS
Talis Biomedical Corp
9 Dec 21
Departure of Directors or Certain Officers
4:11pm
bonus under your existing employment arrangement and targets as the Company’s Chief Commercial Officer. All payments to you from the Company
8-K
EX-99.1
TLIS
Talis Biomedical Corp
10 Nov 21
Talis Biomedical Granted FDA Emergency Use Authorization (EUA) for COVID-19 Molecular Point-of-Care Test to Detect SARS-CoV-2
5:04pm
and tested in point-of-care settings.
The Talis One COVID-19 Test System targets two genes, ORF1ab and N, to optimize sensitivity and the inclusion
10-K
0balkzg
30 Mar 21
Annual report
5:22pm
424B4
hphc09kmn3 05jp6d
12 Feb 21
Prospectus supplement with pricing info
4:31pm
S-1/A
ut4 6xtyp
8 Feb 21
IPO registration (amended)
8:27am
S-1
zye5gby9jg
22 Jan 21
IPO registration
5:18pm
DRS/A
xzq aywyaour
6 Jan 21
Draft registration statement (amended)
12:00am
DRS
b4sa25h5f1
15 Oct 20
Draft registration statement
12:00am
- Prev
- 1
- Next